By Pat Anson, Editor
Multiple sclerosis patients who use an oral cannabinoid spray showed no long-term cognitive impairment or changes in mood, according to a new study released by GW Pharamaceuticals, a British biopharmaceutical company.
The spray, sold under the brand name Sativex, is approved for use in Europe, Canada and Mexico to treat multiple sclerosis (MS) symptoms and cancer pain, but is currently not approved for sale in the United States. GW Pharmaceuticals hopes to see FDA approval by the end of 2013.
“We are pleased to report positive and wholly reassuring results from this 12 month placebo-controlled study in patients with MS spasticity,” said Dr. Stephen Wright, GW Pharmaceuticals research and development director.
“We have now shown that Sativex does not impair cognition either in short-term or in long-term use in well designed, randomized, placebo controlled clinical trials. These data not only confirm the good tolerability of Sativex in long-term use but also provide further evidence of efficacy consistent with that seen in previous shorter duration clinical trials.”
Read more at National Pain Report.
(0) Readers Comments
November 12, 2012
October 08, 2012
September 12, 2012
July 23, 2012
June 11, 2019
April 01, 2019
March 18, 2019
Oh boy...Your right we hate to hear this. You know why people in pain
Doesn't the 1.5 billion is spent a year give credence to its possitive
Many MS drugs cause PML and deaths too these drugs all need t
I knew him when he was breaking in at a couple of Los Angeles TV stati
Saying there is a 'twist' is the worst type of spoile